Mirum Pharmaceuticals, Inc. Amortization of Debt Issuance Costs and Discounts
Mirum Pharmaceuticals, Inc. (MIRM) reported Amortization of Debt Issuance Costs and Discounts of $658.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $658.00K, a 54.10% increase year-over-year.
- Mirum Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $454.00K, a 4.85% increase year-over-year.
- Mirum Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was $436.00K, a 4.81% increase year-over-year.
- Mirum Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was $443.00K, a 4.48% increase year-over-year.
- Mirum Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for fiscal 2025 was $1.74M, a 4.70% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for fiscal 2024 was $1.66M, a 48.70% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for fiscal 2023 was $1.12M.
- Mirum Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for fiscal 2022 was $0.00.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2026-06-30 | $658.00K 10-Q · filed 2026-08-05 | $1.11M 10-Q · filed 2026-08-05 | $1.55M derived: sum of 3 quarters · filed 2026-08-05 | $1.99M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $454.00K 10-Q · filed 2026-05-06 | $890.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.33M derived: sum of 3 quarters · filed 2026-05-06 | $1.76M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $436.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $879.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.31M derived: sum of 3 quarters · filed 2026-08-05 | $1.74M 10-K · filed 2026-02-25 |
| 2025-09-30 | $443.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $870.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.30M 10-Q · filed 2025-11-04 | $1.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $427.00K 10-Q · filed 2026-08-05 | $860.00K 10-Q · filed 2026-08-05 | $1.28M derived: sum of 3 quarters · filed 2026-08-05 | $1.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $433.00K 10-Q · filed 2026-05-06 | $849.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.27M derived: sum of 3 quarters · filed 2026-05-06 | $1.68M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $416.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $840.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.25M derived: sum of 3 quarters · filed 2026-02-25 | $1.66M 10-K · filed 2026-02-25 |
| 2024-09-30 | $424.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $831.00K derived: sum of 2 quarters · filed 2025-11-04 | $1.25M 10-Q · filed 2025-11-04 | $1.64M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $407.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $821.00K 10-Q · filed 2025-08-06 | $1.22M derived: sum of 3 quarters · filed 2026-02-25 | $1.63M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $414.00K 10-Q · filed 2025-05-07 | $813.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.22M derived: sum of 3 quarters · filed 2026-02-25 | $1.53M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $399.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $810.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.12M derived: sum of 3 quarters · filed 2026-02-25 | $1.12M 10-K · filed 2026-02-25 |
| 2023-09-30 | $411.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $718.00K derived: sum of 2 quarters · filed 2024-11-12 | $718.00K 10-Q · filed 2024-11-12 | $718.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $307.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $307.00K 10-Q · filed 2024-08-07 | $307.00K derived: sum of 3 quarters · filed 2025-02-26 | $307.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-07 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |